Article Text

Download PDFPDF

Allen Carr’s Easyway to Stop Smoking - A randomised clinical trial
  1. Sheila Keogan,
  2. Shasha Li,
  3. Luke Clancy
  1. TobaccoFree Research Institute Ireland, Focas Research Institute, DIT, Dublin 8, Dublin, Ireland
  1. Correspondence to Professor Luke Clancy, TobaccoFree Research Institute Ireland, Focas Research Institute, DIT, Dublin 8, Dublin, Ireland; lclancy{at}


Objective To determine if Allen Carr’s Easyway to Stop Smoking (AC) was superior to in a randomised clinical trial (RCT).

Setting Single centre, open RCT, general population based.

Participants 300 adult smokers, 18 years plus, minimum 5 cigarettes daily, and English speaking. AC, 151 (females 44.4%) and, 149 (females 45.6%), mean age 44 years. outcomes for all 300 were analysed (intention-to-treat). Recruited through advertisement from July 2015 to February 2016.

Intervention Randomly assigned to AC (n=151) and (n=149), matched for age, sex and education. Block randomisation, enrolment and follow-up at 1, 3, 6 and 12 months. Primary aim was to determine if AC had higher quit rates than service at 3 months. Secondary aims: quit rates at 1, 6 and 12 months and analysis of associated factors including weight. AC consisted of a 5-hour seminar, in a group setting. is an online portal for smoking cessation.

Results AC had higher quit rates at 1, 3, 6 and 12 months. AC: 38%, (n=57), 27% (n=40), 23% (n=35), 22% (n=33) vs 20% (n=30), 15% (n=22), 15% (n=23), 11% (n=17), respectively (all p values <0.05). Logistic regression AC vs, OR 2.26 (95% CI 1.22 to 4.21) p value=0.01. Weight gain 3.8 kg in AC vs 1.8 kg in (p value <0.05).

Conclusions All AC quit rates were superior to, outcomes were comparable with established interventions.

Trial registration number ISRCTN12951013. Recruitment July 2015–February 2016.

  • Cessation
  • Addiction
  • Health Services
  • Nicotine

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors LC conceived the study. SK and LC designed the study and were responsible for the conduct of the study. SK was mainly responsible for the conduct of the trial with LC as principal investigator. SL and SK did the literature search and were involved in analysis of the data. SK drafted the first version of the manuscript with input from LC. LC and SL had input into all redrafts. All authors read and approved the final version.

  • Funding DOH Ireland Grant: NL14/1.

  • Competing interests LC was involved in the Cease of NRT conducted on behalf of the ERS by the Occupational and Epidemiology Assembly and with the sponsorship of Pharmacia & Upjohn, Helsingborg, Sweden. He has served on advisory Boards for Pfizer and has in the past received research grants from Pfizer for Tobacco Control projects but none for smoking cessation. SK and SL declare no competing interest.

  • Patient consent Obtained.

  • Ethics approval Dublin Institute of Technology, Research Ethics Committee: Ethical Clearance Ref 14-94.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement The authors are open to data sharing of de-identified data collected at all follow-up visits from both conditions. Application with rationale may be made to corresponding author at or